It’s the Peptide-MHC Affinity, Stupid
Authors:
- Thomas BlankensteinTBThomas Blankenstein
- 1 April 2013
- journal article
- editorial
- Published by Elsevier in Cancer Cell
- Vol. 23 (4) , 429-431
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Relapse or Eradication of Cancer Is Predicted by Peptide-Major Histocompatibility Complex AffinityCancer Cell, 2013
- Molecular Pathways: Comparing the Effects of Drugs and T Cells to Effectively Target OncogenesClinical Cancer Research, 2013
- The determinants of tumour immunogenicityNature Reviews Cancer, 2012
- Long-term Persistence of CD4+ but Rapid Disappearance of CD8+ T Cells Expressing an MHC Class I-restricted TCR of Nanomolar AffinityMolecular Therapy, 2012
- Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigenBlood, 2009
- T‐cell receptor binding affinities and kinetics: impact on T‐cell activity and specificityImmunology, 2009
- Balancing between Antitumor Efficacy and Autoimmune Pathology in T-Cell–Mediated Targeting of Carcinoembryonic AntigenCancer Research, 2008
- Quo Vadis, Specificity?Science, 2008
- T-cell-receptor gene therapyNature Reviews Immunology, 2002